Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 037326105 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Commodore Capital LP
13G
|
9.9% |
3/16/2026
Event 3/9/2026
|
||
| Commodore Capital LP | 9.9% | |||
| Commodore Capital Master LP | 9.9% | |||
| Robert Egen Atkinson | 9.9% | |||
| Michael Kramarz | 9.9% | |||
|
Coastlands Capital Partners LP
13G
|
9.3% |
6/4/2025
Event 5/28/2025
|
||
| Coastlands Capital LP | 9.3% | |||
| Coastlands Capital Partners LP | 9.3% | |||
| Coastlands Capital GP LLC | 9.3% | |||
| Coastlands Capital LLC | 9.3% | |||
| Matthew D. Perry | 9.3% | |||
|
Vivo Opportunity Fund Holdings, L.P.
13G
|
8.0% |
3/13/2026
Event 3/10/2026
|
||
| Vivo Opportunity Fund Holdings, L.P. | 8.0% | |||
| Vivo Opportunity, LLC | 8.0% | |||
| Vivo Opportunity Cayman Fund, L.P. | 0.8% | |||
| Vivo Opportunity Cayman, LLC | 0.8% | |||
|
Adjuvant Global Health Technology Fund, L.P.
13G/A
|
7.9% |
2/28/2025
Event 12/31/2024
|
||
| Adjuvant Global Health Technology Fund, L.P. | 6.7% | |||
| Adjuvant Global Health Technology Fund DE, L.P. | 1.3% | |||
| Adjuvant Capital GP, L.P. | 7.9% | |||
| Adjuvant Capital Management, L.L.C. | 7.9% | |||
| Eric Easom 13G/A | 7.9% |
2/13/2026
Event 12/31/2025
|
||
|
Integrated Core Strategies (US) LLC
13G
|
6.3% |
3/13/2026
Event 3/6/2026
|
||
| Integrated Core Strategies (US) LLC | 6.0% | |||
| Millennium Management LLC | 6.3% | |||
| Millennium Group Management LLC | 6.3% | |||
| Israel A. Englander | 6.3% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (6) | ||||
| Almitas Capital LLC 13G/A | 4.1% |
5/15/2026
Event 3/31/2026
|
||
| Brii Biosciences Ltd 13G/A | 3.1% |
2/14/2025
Event 12/31/2024
|
||
| BML Investment Partners, L.P. 13D/A | 1.4% |
6/18/2025
Event 6/17/2025
|
||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
|
0% |
2/14/2025
Event 12/31/2024
|
||
| Frazier Life Sciences Public Fund, L.P. | 0% | |||
| FHMLSP, L.P. | 0% | |||
| FHMLSP, L.L.C. | 0% | |||
| Frazier Life Sciences X, L.P. | 0% | |||
| FHMLS X, L.P. | 0% | |||
| FHMLS X, L.L.C. | 0% | |||
| Frazier Life Sciences XI, L.P. | 0% | |||
| FHMLS XI, L.P. | 0% | |||
| FHMLS XI, L.L.C. | 0% | |||
| James N. Topper | 0% | |||
| Patrick J. Heron | 0% | |||
| Albert Cha | 0% | |||
| James Brush | 0% | |||
| Daniel Estes | 0% | |||
|
RA Capital Management, L.P.
13G/A
|
0% |
2/14/2025
Event 12/31/2024
|
||
| RA Capital Management, L.P. | 0% | |||
| Peter Kolchinsky | 0% | |||
| Rajeev Shah | 0% | |||
| RA Capital Healthcare Fund, L.P. | 0% | |||
|
TCG Crossover GP I, LLC
13G/A
|
0% |
2/14/2025
Event 12/31/2024
|
||
| TCG Crossover GP I, LLC | 0% | |||
| TCG Crossover Fund I, L.P. | 0% | |||
| Chen Yu | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 191 | $1.02 k |
| 2026 Q2 | 66 | 24.6 M | $119 M |
| 2026 Q1 | 52 | 21.9 M | $74.8 M |
| 2025 Q4 | 38 | 8.67 M | $9.88 M |
| 2025 Q3 | 37 | 9.71 M | $12.3 M |
| 2025 Q2 | 38 | 8.29 M | $8.78 M |
| 2025 Q1 | 39 | 14.3 M | $19.5 M |
| 2024 Q4 | 39 | 14.5 M | $20.1 M |
| 2024 Q3 | 33 | 13.5 M | $14.5 M |
| 2024 Q2 | 49 | 19.5 M | $42.0 M |
| 2024 Q1 | 57 | 18.7 M | $60.9 M |
| 2023 Q4 | 55 | 20.7 M | $423 M |
| 2023 Q3 | 38 | 19.9 M | $320 M |
| 2023 Q2 | 32 | 11.7 M | $99.9 M |
| 2023 Q1 | 40 | 9.60 M | $94.8 M |
| 2022 Q4 | 38 | 9.85 M | $93.8 M |
| 2022 Q3 | 39 | 9.50 M | $165 M |
| 2022 Q2 | 37 | 9.39 M | $72.4 M |
| 2022 Q1 | 19 | 8.95 M | $134 M |